In light of de-escalation data, for patients undergoing standard dose radiation for favorable HPV + oropharynx cancer, do you accept lower coverage of the low-dose RT field to better spare OARS?

I do not compromise PTV coverage to spare non-critical OARs in patients treated with curative intent for head and neck cancer. What is important to consider (and what I suspect this question may be getting at) is that dose and target selection are critical to reducing the dose to non-critical but fu...